Royal Bank of Canada’s Insys Therapeutics, Inc. INSY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-3,760
Closed -$17K 7432
2019
Q1
$17K Sell
3,760
-4,570
-55% -$21.6K ﹤0.01% 5742
2018
Q4
$29K Sell
8,330
-22,005
-73% -$153K ﹤0.01% 5406
2018
Q3
$306K Sell
30,335
-55
-0.2% -$439 ﹤0.01% 4229
2018
Q2
$220K Sell
30,390
-2,484
-8% -$17.3K ﹤0.01% 4355
2018
Q1
$199K Sell
32,874
-1,955
-6% -$16.1K ﹤0.01% 4326
2017
Q4
$335K Buy
34,829
+5,727
+20% +$37.5K ﹤0.01% 4086
2017
Q3
$258K Buy
29,102
+15,407
+113% +$159K ﹤0.01% 4327
2017
Q2
$173K Buy
13,695
+6,877
+101% +$81.4K ﹤0.01% 4452
2017
Q1
$72K Buy
6,818
+4,370
+179% +$46.6K ﹤0.01% 4952
2016
Q4
$23K Sell
2,448
-497
-17% -$5.62K ﹤0.01% 5704
2016
Q3
$34K Buy
2,945
+662
+29% +$10.1K ﹤0.01% 5338
2016
Q2
$29K Sell
2,283
-103
-4% -$1.5K ﹤0.01% 5358
2016
Q1
$38K Buy
2,386
+1,639
+219% +$31.1K ﹤0.01% 5248
2015
Q4
$21K Sell
747
-1,213
-62% -$33.6K ﹤0.01% 5702
2015
Q3
$56K Sell
1,960
-8,828
-82% -$325K ﹤0.01% 5071
2015
Q2
$387K Buy
10,788
+10,598
+5,578% +$330K ﹤0.01% 3852
2015
Q1
$6K Sell
190
-2,660
-93% -$70.3K ﹤0.01% 5708
2014
Q4
$60K Sell
2,850
-1,150
-29% -$22.7K ﹤0.01% 4977
2014
Q3
$78K Buy
4,000
+800
+25% +$12.6K ﹤0.01% 4741
2014
Q2
$50K Sell
3,200
-250
-7% -$4.04K ﹤0.01% 4843
2014
Q1
$71K Buy
3,450
+1,950
+130% +$38.7K ﹤0.01% 4707
2013
Q4
$19K Sell
1,500
-26,952
-95% -$374K ﹤0.01% 5281
2013
Q3
$332K Buy
+28,452
New +$234K ﹤0.01% 3715

Other funds holding INSY

Royal Bank of Canada's INSY Position: Q2 2019 in Review

Royal Bank of Canada sold out of Insys Therapeutics, Inc. (INSY) in Q2 2019, closing a stake of 3,760 shares — an estimated $17K sold.

Royal Bank of Canada first reported a position in INSY in Q3 2013 and held it in 23 quarters. The position peaked at $387K in Q2 2015. 16 funds tracked by Wall St. Rank hold INSY as of Q2 2019.

  • Royal Bank of Canada reported no remaining Insys Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Royal Bank of Canada sold 3,760 Insys Therapeutics, Inc. shares in Q2 2019, an estimated $17K.
  • Royal Bank of Canada first reported a position in Insys Therapeutics, Inc. in Q3 2013 and held it in 23 quarters.
  • Royal Bank of Canada's Insys Therapeutics, Inc. position peaked at $387K in Q2 2015.
  • 16 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2019.

Based on Royal Bank of Canada's 13F filing for Q2 2019, filed 14 Aug 2019.